Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for scPharmaceuticals, Inc. (SCPH : NSDQ)
 
 • Company Description   
scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company's pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States.

Number of Employees: 164

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.48 Daily Weekly Monthly
20 Day Moving Average: 254,800 shares
Shares Outstanding: 52.79 (millions)
Market Capitalization: $236.51 (millions)
Beta: 0.38
52 Week High: $5.65
52 Week Low: $1.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 12.28% 8.06%
12 Week 75.00% 44.00%
Year To Date 26.55% 18.74%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
25 BURLINGTON MALL ROAD SUITE 203
-
BURLINGTON,MA 01803
USA		 ph: 617-517-0730
fax: -		 tignelzi@scpharma.com http://www.scpharmaceuticals.com
 
 • General Corporate Information   
Officers
John H. Tucker - Chief Executive Officer;President
Jack A. Khattar - Chairman of the Board and Director
Rachael Nokes - Chief Financial Officer
William T. Abraham - Director
Mette Kirstine Agger - Director

Peer Information
scPharmaceuticals, Inc. (CORR.)
scPharmaceuticals, Inc. (RSPI)
scPharmaceuticals, Inc. (CGXP)
scPharmaceuticals, Inc. (BGEN)
scPharmaceuticals, Inc. (GTBP)
scPharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 810648105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 52.79
Most Recent Split Date: (:1)
Beta: 0.38
Market Capitalization: $236.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 5.63
EPS Growth
vs. Year Ago Period: 5.56%
vs. Previous Quarter: 2.86%
Sales Growth
vs. Year Ago Period: 92.59%
vs. Previous Quarter: -3.28%
ROE
06/30/25 - -
03/31/25 - -594.07
12/31/24 - -345.98
ROA
06/30/25 - -
03/31/25 - -73.54
12/31/24 - -71.54
Current Ratio
06/30/25 - -
03/31/25 - 5.48
12/31/24 - 7.12
Quick Ratio
06/30/25 - -
03/31/25 - 4.61
12/31/24 - 6.18
Operating Margin
06/30/25 - -
03/31/25 - -170.34
12/31/24 - -185.32
Net Margin
06/30/25 - -
03/31/25 - -216.24
12/31/24 - -234.36
Pre-Tax Margin
06/30/25 - -
03/31/25 - -216.24
12/31/24 - -234.36
Book Value
06/30/25 - -
03/31/25 - -0.10
12/31/24 - 0.27
Inventory Turnover
06/30/25 - -
03/31/25 - 0.85
12/31/24 - 0.80
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 3.86
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 79.40
 

Powered by Zacks Investment Research ©